Assessment and documentation in the patient record by a pharmacist is required prior to initial drug provision *(new admission or new starts)*. Form submission is required within six weeks following admission or upon completion of the pregabalin trial.

**Processing Instructions:** Please complete the form in its entirety.

Pharmacy provider email to ISFL Long Term Care Pharmacist at:

cc.drugmanagement@albertahealthservices.ca **OR** pharmacist/physician fax to **403-943-0232**

|  |  |
| --- | --- |
| Funding Eligibility [ ]  New Start  [ ]  New Admission  | Date started *(yyyy-Mon-dd)*       |
| Resident Code       | Year of Birth *(yyyy)*      | Date of Admission *(yyyy-Mon-dd)*      |
| Prescribing Information *(reason for prescribing, specialist or clinic involvement)*       | Dosing Information      |
| **Protocol 1**: **New Start / Step Therapy** |
| Formulary first-line: GabapentinFor treatment of neuropathic pain associated with diabetic neuropathy, post-herpetic neuralgia, spinal cord injury or pain associated with fibromyalgia.  | **Criteria met / acknowledged**  |
|  | * The resident must have **failed** an **adequate trial** of therapy with the Formulary first-line agent **gabapentin**: Outcome of gabapentin trial *(specify date and outcome):*      ; **and**

*A* ***failed*** *gabapentin trial occurs when dosage titration to achieve pain control is not possible due to renal function and/or unacceptable or non-resolving side effects which are impairing function, such as somnolence or cognitive impairment. An* ***adequate******trial*** *is defined as a separate treatment course of gabapentin (which may involve more than gabapentin) used for a period of 4 to 6 weeks.** Must complete a **pregabalin trial.** A pregabalin trial of 4 to 6 weeks is used to determine objective and subjective improvement in symptoms from baseline and compared to gabapentin. Outcomes ofpregabalin trial *(specify date and outcome)*:**; and**
* The Interdisciplinary team has reviewed and incorporated non-pharmacological pain management strategies into the resident’s care plan; **and**
* Pregabalin will be assessed with regular medication reviews for determination of ongoing benefit.
 | **[ ]** **[ ]** **[ ]** **[ ]**  |

|  |
| --- |
| **Protocol 2**: **Continuation of Therapy on Admission** |
| For treatment of neuropathic pain associated with diabetic neuropathy, post-herpetic neuralgia, spinal cord injury or pain associated with fibromyalgia | **Criteria met / acknowledged** |
| * The resident failed a previous adequate trial of gabapentin; **or**
* Pregabalin was recommended by a specialist (e.g. Pain Clinic); **and**

*The physician & pharmacist use clinical judgment to evaluate whether changing therapy to the formulary first-line agent gabapentin should be (re)considered.** Interdisciplinary team have reviewed and incorporated non-pharmacological pain management strategies into the resident’s care plan; **and**
* Pregabalin will be assessed with regular medication reviews for determination of ongoing benefit.
 | [ ] [ ] **[ ]** **[ ]**  |
| **Funding may be declined or terminated by Calgary Zone LTC Drug Management when criteria are not met and/or maintained.**  |
| By submitting this application, the care team and pharmacist have given reasonable considerations to consent, alternative therapeutic options *(including formulary alternatives)*, and risks/benefits. |
| Pharmacist Name       | Initial Drug Provision Date *(yyyy-Mon-dd)*      |
| Physician Name       | Tracking Code *(generated by Pharmacist)*-(MonYY)-(RPh initials) |